Table 1.
The forward MR analysis on TL and hematologic malignancies
| Outcome | nSNP | Methods | P value∗ | OR | CI (95%) | P (heterogeneity) | P (pleiotropy) | MR-PRESSO | |
|---|---|---|---|---|---|---|---|---|---|
| MR-Egger | IVW | ||||||||
| Primary lymphoid and hematopoietic malignant neoplasms | 116 | MR-Egger | 7.53E−6 | 2.083 | 1.533–2.829 | 0.000 | 0.000 | 0.073 | 0.008 |
| WM | 4.61E−8 | 1.917 | 1.518–2.420 | ||||||
| IVW | 2.69E−8 | 1.651 | 1.383–1.970 | ||||||
| AML | 112 | MR-Egger | 0.481 | 0.546 | 0.102–2.924 | 0.330 | 0.307 | 0.170 | 0.297 |
| WM | 0.447 | 1.746 | 0.436–6.991 | ||||||
| IVW | 0.384 | 1.488 | 0.608–3.640 | ||||||
| CML | 115 | MR-Egger | 0.752 | 1.318 | 0.239–7.273 | 0.096 | 0.106 | 0.804 | 0.112 |
| WM | 0.117 | 2.938 | 0.761–11.345 | ||||||
| IVW | 0.322 | 1.583 | 0.638–3.930 | ||||||
| ALL | 115 | MR-Egger | 0.010 | 10.901 | 1.842–64.516 | 0.748 | 0.692 | 0.071 | 0.713 |
| WM | 0.244 | 2.369 | 0.545–10.289 | ||||||
| IVW | 0.041 | 2.690 | 1.040–6.956 | ||||||
| CLL | 115 | MR-Egger | 0.087 | 2.479 | 0.884–6.953 | 0.943 | 0.950 | 0.756 | 0.956 |
| WM | 0.144 | 1.813 | 0.819–4.015 | ||||||
| IVW | 0.005 | 2.155 | 1.265–3.671 | ||||||
| Leukemia of unspecified cell type | 114 | MR-Egger | 0.465 | 1.844 | 0.360–9.453 | 0.879 | 0.887 | 0.562 | 0.882 |
| WM | 0.039 | 4.209 | 1.057–16.766 | ||||||
| IVW | 0.021 | 2.779 | 1.164–6.631 | ||||||
| Multiple myeloma | 117 | MR-Egger | 0.005 | 4.001 | 1.546–10.352 | 0.252 | 0.198 | 0.058 | 0.191 |
| WM | 0.026 | 2.661 | 1.145–6.187 | ||||||
| IVW | 0.024 | 1.845 | 1.083–3.142 | ||||||
| Hodgkin lymphoma | 118 | MR-Egger | 0.270 | 1.506 | 0.730–3.107 | 0.316 | 0.336 | 0.691 | 0.344 |
| WM | 0.379 | 1.337 | 0.696–2.566 | ||||||
| IVW | 0.014 | 1.697 | 1.115–2.583 | ||||||
| NHL | 117 | MR-Egger | 0.035 | 2.177 | 1.064–4.457 | 0.058 | 0.061 | 0.449 | 0.058 |
| WM | 0.006 | 2.658 | 1.323–5.341 | ||||||
| IVW | 0.009 | 1.737 | 1.145–2.636 | ||||||
∗Bold values indicate significant results.